In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

United Nations members unanimously adopted a high-level political declaration on universal health coverage (UHC), but while the adoption of the declaration is welcome news, in many ways it represents a starting point for the next phase of UHC, in which the thornier issues of financing, follow through, and accountability will rise to the forefront.

Against a backdrop of mounting global health challenges, the 72nd World Health Assembly (WHA) convened last week, with politicians, philanthropists, business executives, and civil society leaders all descending upon Geneva. GHTC was on the scene—attending side events, technical briefings, and following the official agenda. Here are our top four takeaways from this year’s assembly.

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

A “who’s who” of politicians, philanthropists, CEOs, and civil society leaders descended upon New York City this week for the annual United Nations General Assembly (UNGA). GHTC was there, serving as your eyes and ears on the ground. Here is what we heard and our top four takeaways on global health R&D.

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

2018 is shaping up to be another important year for US policy related to global health and medical research. As Congress returns for a busy work session and the White House continues to roll out policy reforms, here are the top five issues GHTC will be following in 2018.

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

As the year comes to an end, GHTC is reflecting on the top stories in global health innovation that made news 2016. 

The 71st United Nations General Assembly (UNGA) concluded this week. Breakthroughs gives a synopsis of the key global health R&D issues discussed at the assembly and what actions were taken.

At the United Nations General Assembly, world leaders made an unprecedented collective commitment to fighting the growing problem of antimicrobial resistance. GHTC and Global Health Council analyze what that commitment entails, why it matters, and the importance of what happens next.

The midtown Manhattan mayhem begins with the opening of the 71st United Nations General Assembly. GHTC preview the global health policy issues that will be discussed at this year's assembly.

This coming week the “who’s who” of the global health community (as well as some much more modest global health advocates such as your humble author) will make the annual trek to Geneva, Switzerland, for the 69th World Health Assembly (WHA), where World Health Organization (WHO) member states will collectively decide WHO’s plans for the coming year.

Later this month global leaders are poised to approve the Sustainable Development Goals (SDGs), but a new report commissioned by a leading group of health nonprofits including GHTC warns that the SDG targets will not be achieved without the development and introduction of new and improved health technologies to address the health needs of the world’s poorest people.

Trying to navigate and understand the post-2015 negotiations can be a challenge, so to help add some clarity, last week the Global Health Technologies Coalition (GHTC) convened a panel of experts to help explain the ongoing debates and where the negotiations stand and how health innovation is reflected in the agenda.

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

In this guest post, Claire Wingfield—product development policy officer at PATH—writes about a new paper exploring why research and development (R&D) of high-priority health tools for diseases and conditions affecting low- and middle-income countries (LMICs) should be a critical component of the post-2015 development agenda.

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.